

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 123-8 (PROGRAM MEDICINES)

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
1	ACULIFE HEALTHCARE PRIVATE LIMITED	Firm Remarks: The firm may be considered with all products			
		2262	Dextrose 10 Percentage I.V 500 ml		May be considered
		1304	Lipids I.V. 20 Percentage In 250ml Bottles		May be considered
		655	Water for Injection IP 10 ml amp		May be considered
2	Appasamy Ocular Devices (P) Ltd.	Firm Remarks: The firm may be considered with all products			
		1141	Atropine Sulphate eye Drops BP 1 Percentage 5 ml		May be considered
		2299	Gatifloxacin (0.3 percentage w/w) plus Dexamethasone (0.1 percentage w/w) eye Drops in 5ml		May be considered
3	CENTURION REMEDIES PRIVATE LIMITED	Firm Remarks: May be considered for products at S.No. 3, 4, 5, 7, 8, 9, 11, 13, 15, 16, 19, 20, 21, 23, 24, 29, 31, 32, 34, 35, 36, 37, 38, 40 &41 Firm may be considered (1) Products S.No. 1, 6, 10, 12, 14, 18, 22, 25, 26, 27, 33 and 42 (2) Products at S.No. 2, 17, 28, 30 and 39 may be considered based on decision of APMSIDC based on requirement of user department			
		4038	0.025percentage strength of Triamcinoloneacetonidegel with 15ml/gel	Not submitted May be considered after submission of product approval	May not be considered
		4035	0.2percentage Strength of Chlorhexidine Gluconate with 40 mg/ml (mouth rinse)	The firm submitted product approval for Chlorhexidine Gluconate solution IP 0.2% w/v at p.no.16 Decision may be taken by the APMSIDC basing on the requirement of the user department	May not be considered
		4034	0.4percentage strength for Stannous Fluoride Gel with 150 gm/gel		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		4033	5percentage of Potassium Nitrate with 50 gm/gel		May be considered
		30	Acetazolamide Tablets IP 250 mg		May be considered
		2452	Activated Charcoal Tablets IP 500mg	Firm has not submitted product approval for IP grade product at p.no.26 May be considered after submission of approval for IP grade product	May not be considered
		1738	Atamoxetine Capsules 10mg		May be considered
		1747	Buspirone Tablets IP 5mg		May be considered
		2238	Chlordiazepoxide Tablets 25mg		May be considered
		1770	Cyclophosphamide Tablets IP 50mg	Not submitted May be considered after submission of product approval	May not be considered
		412375	Dextromethorphan oral Syrup 60 ml		May be considered
		1800	Etoposide Capsules IP 100 mg	Not submitted May be considered after submission of product approval	May not be considered
		1808	Flunarazine Tablets 5mg		May be considered
		1812	Flutamide Tablets USP 250 mg	Not submitted May be considered after submission of product approval	May not be considered
		299.01	Glibenclamide Tablet 2.5 mg		May be considered
		299	Glibenclamide Tablet 5 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1855	Levamisole Tablets IP 150mg	Submitted at p.no. 45 Levamisole Hcl tablets IP 150mg May be considered as per the decision of APMSIDC on the requirement of the user department	May not be considered
		2152.02	Lopinavir 40mg plus Ritonavir 10mg	Not submitted May be considered after submission of product approval	May not be considered
		2337	Lorazepam Tablet 2mg		May be considered
		1866	Mefloquine Hcl IP Tablets 250mg		May be considered
		2340	Memantine 10mg Tablet		May be considered
		1870	Mercaptopurine Tablets IP 50 mg	Not submitted May be considered after submission of product approval	May not be considered
		2342	Mesalazine Tablet 1.2 gm		May be considered
		1873	Methimazole Tablet 5mg		May be considered
		1874	Methotrexate Tablets IP 2.5 mg	Not submitted May be considered after submission of product approval	May not be considered
		4036	Metronidazole ointment (1.5percentage w/w of metronidazole 20 gm for oral use)	Firm has submitted license for Metronidazole Gel USP 1.5% w/w but in tender document the product is Metronidazole Ointment 1.5% w/w May be considered after submission of product approval for ointment form as required	May not be considered
		412374	Normal Saline nasal Drops 20ml	Not submitted May be considered after submission of product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1906	Oxybutynin Tablets BP 2.5mg	Submitted product approval for Oxybutynin Tablets IP 2.5mg at p.no. 49 May be considered as per the decision of APMSIDC based on the requirement of the user department	May be considered
		1914	Praziquantel Tablets IP 600 mg		May be considered
		1925	Pyridostigmine Tablets BP 60 mg	The firm has submitted product approval for Pyridostigmine tablets IP 60mg at p.no. 35 May be considered as per the decision of APMSIDC based on the requirement of the user department	May be considered
		2407	Risperidone 0.5mg Tablet		May be considered
		2410	Ropinirole ER Tablets 1 mg		May be considered
		2421	Sertaconazole Nitrate powder 2 Percentage w/w 100gram bottle	Not submitted May be considered after submission of product approval	May not be considered
		1957	Sumatriptan Succinate Tablets BP 50mg		May be considered
		2087.01	Tab Entacavir 1mg		May be considered
		1961	Tacrolimus Capsules 5 mg		May be considered
		4037	Tannic acid plus zinc chloride and cetramide, Volume 15 ml (Gum Paint)		May be considered
		1968	Tolterodine Tartrate Capsules 2mg		May be considered
		1908	Trichlofos BP 500mg/5ml BP	Firm has submitted license for Trichlofos Oral solution IP 500mg/5ml at p.no 42 May be considered as per the decision of APMSIDC based on the requirement of the user department	May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1971	Trimetazidine Tablets 20mg		May be considered
		1976	Warfarin sodium Tablets IP 3 mg		May be considered
		412372	Zinc Oxide Cream 10percentage 100 g	Not submitted May be considered after submission of product approval	May not be considered
4	CIPCO PHARMACEUTICALS	Firm Remarks: The firm may be considered with all products			
		2167.01	Iron Folic Acid small pink Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
5	CIPLA LTD	Firm Remarks: The firm may be considered with applied product			
		1656	Salbutamol Nebulising solution IP 15ml		May be considered
6	Cyano Pharma Private Limited	Firm Remarks: The firm may be considered with applied product			
		2167.01	Iron Folic Acid small pink Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
7	Glenmark Pharmaceuticals Ltd	Firm Remarks: The firm may be considered with applied product			
		2289	Flucinolone Acetonide 0.1 Percentage w/w cream 30 gm		May be considered
		2290	Flucinolone Acetonide 0.01 Percentage w/w Lotion 30 ml		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
8	HEALTHY LIFE PHARMA PRIVATE LIMITED	Firm Remarks: The firm may be considered with applied product			
		2167.01	Iron Folic Acid small pink Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
9	LUPIN LIMITED	Firm Remarks: The firm may be considered with applied product			
		422084	Ferric Carboxy Maltose Injection 500mg in 10ml vial		May be considered
10	MSD Pharmaceuticals Private Limited	Firm Remarks: The firm may be considered with applied product			
		2395	Quadrivalent Human Pappiloma Virus Vaccine Injection (0.5ml PFS)		May be considered
11	Mylan Laboratories Limited	Firm Remarks: The firm may be considered with applied product			
		2427	Sofosbuvir 400mg plus Valpatasvir 100mg tablets		May be considered
12	NESTOR PHARMACEUTICALS LIMITED	Firm Remarks: The firm may be considered with applied products			
		2167.01	Iron Folic Acid small pink Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
13	SPECTRUM FORMULATION PRIVATE LIMITED	Firm Remarks: Except 1 & 2 other products may be considered after submission of product approval			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1808	Flunarazine Tablets 5mg		May be considered
		1874	Methotrexate Tablets IP 2.5 mg		May be considered
		4036	Metronidazole ointment (1.5percentage w/w of metronidazole 20 gm for oral use)	Not submitted product approval May be considered after submission of product approval	May not be considered
		2407	Risperidone 0.5mg Tablet	Not submitted product approval May be considered after submission of product approval	May not be considered
		1961	Tacrolimus Capsules 5 mg	Not submitted product approval May be considered after submission of product approval	May not be considered
		1971	Trimetazidine Tablets 20mg	Not submitted product approval May be considered after submission of product approval	May not be considered
		412372	Zinc Oxide Cream 10percentage 100 g	Not submitted product approval May be considered after submission of product approval	May not be considered
14	SUDARSHAN PHARMACEUTICALS PVT LTD	Firm Remarks: The firm was blacklisted by KSMSCL, Hence the firm along with products not considered			
		2167.01	Iron Folic Acid small pink Sugar coated Tablets		May not be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May not be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May not be considered
15	THE SWASTIKPHARMACEUTICALS	Firm Remarks: The firm may be considered with applied products			

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		4035	0.2percentage Strength of Chlorhexidine Gluconate with 40 mg/ml (mouth rinse)		May be considered

Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00.PM on 24.09.2022 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 123-8 (Medicines) TEC Report to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 123-8(Medicines) TEC Report.